Invivyd (IVVD) EBT Growth (3y) (2024 - 2025)

Invivyd (IVVD) EBT Growth (3y) (2024 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Oculis Holding AG 65,719.23 Bn 65,718.94 Bn - 9.34%
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 471.85 Bn 467.06 Bn 1.35 Bn 40.43%
5 Vertex Pharmaceuticals 122.29 Bn 115.04 Bn 2.59 Bn 12.01%
6 Regeneron Pharmaceuticals 70.04 Bn 61.28 Bn 3.31 Bn -1.05%
7 Belite Bio 62.06 Bn 62.06 Bn - -
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn 86.16%
9 Alnylam Pharmaceuticals 37.47 Bn 34.47 Bn 959.66 Mn 48.67%
10 Invivyd 104.00 Mn -122.69 Mn 16.07 Mn 36.77%

Historic Data

Download Data
DateValue
Dec 31, 2025 36.77%
Sep 30, 2025 39.49%
Jun 30, 2025 35.96%
Mar 31, 2025 46.42%
Dec 31, 2024 39.41%
Sep 30, 2024 54.06%
Jun 30, 2024 25.92%
Mar 31, 2024 -26.92%